Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment

US5980908A · kind A · utility

Assignee

• ALFA LAVAL CORPORATE AB · SE

Inventors

• Magnus Hook · Houston, US
• Kjell Martin Lindberg · Uppsala, SE
• Torkel M. Wadstrom · Lund, SE

Key dates

• Filing date: Sep 10, 1993
• Grant date: Nov 9, 1999
• Expiry date: Sep 10, 2013

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S424/823
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention is concerned with a vaccine composition comprising an effective amount of an isolated protein derived from Staphylococcal aureus having the ability to bind fibronectin. The protein has a molecular weight of 165,000 daltons and optionally also contains a protein having a molecular weight of 87,000 daltons. The protein has the ability to elicit antibody production and a level of protein to elicit antibody production. The level of protein is sufficient to produce protection upon challenge with a Staphylococcus aureus bacterial strain in a mammal, particularly a ruminant, by forming antibodies against the Staphylococcus aureus bacterial strain.